Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
63 64 Next >
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Wegovy was just approved in China. 
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
The market for weight loss medicines keeps getting hotter and hotter. 
Via The Motley Fool
This Is Massive News for Eli Lilly Investors
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate. 
Via The Motley Fool
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review
Software, small caps and megacaps were standouts. 
Via Investor's Business Daily
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock. 
Via Chartmill
A Closer Look at Novo Nordisk's Options Market Dynamics
Via Benzinga
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Consider buying shares in these pharma companies, each of which is a leader in the weight loss drug sector. 
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These healthcare stocks have clear paths to growth over the next few years. 
Via The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
Via Benzinga
Volkswagen Puts Our Rivian Bet In The Black: The Pros And Cons Of Trading Options Versus Stocks
Novo Nordisk, Carvana, And Now Rivian 
Via Benzinga
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the world's most populous country. The competitive landscape and regulatory... 
Via Benzinga
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a single supplier with previously unreported ties to fraud and bankruptcy. 
Via Benzinga
Topics Fraud Supply Chain
Exposures Legal Supply Chain
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent... 
Via Benzinga
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Via Benzinga
Novo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge
Novo Nordisk announced the failure of its phase 3 CLARION-CKD trial, which investigated ocedurenone for treating uncontrolled hypertension in advanced chronic kidney disease patients. The trial did not... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
The next trillion dollar stocks have emerged in a few key areas that investors should understand in greater detail in order to profit. 
Via InvestorPlace
Better Growth Stock: Archer Aviation or Viking Therapeutics?
Which one of these potential disruptors is the better buy? 
Via The Motley Fool
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, U.S. stocks showed mixed results. The Dow Jones Industrial Average closed down by nearly 0.8%, finishing at 39,112.16 
Via Benzinga
Topics Stocks
Exposures US Equities
Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, raising concerns for similar weight loss drugs. 
Via Benzinga
Why Novo Nordisk Shares Are Trading Higher Tuesday
The company's weight loss drug Wegovy has been approved in China, the second most populated country that is estimated to have the world's highest number of overweight individuals, according to... 
Via Benzinga
Novo Nordisk Wins Approval For Its Weight-Loss Drug From China
China approved the sale of Novo Nordisk's Wegovy on Tuesday. The drugmaker also announced a $4.1 billion investment in the U.S. Novo Nordisk stock climbed 3.0% to an all-time high this morning. 
Via Talk Markets
European Stocks Dip As US Market Sentiment Sours
European stocks declined as U.S. market sentiment soured, with the Stoxx 600 index down 0.41% by mid-morning. Novo Nordisk shares rose 1.5% following the approval of its weight loss treatment in... 
Via Talk Markets
Why Is Regis (RGS) Stock Up 215% Today?
Regis stock is up on Tuesday with heavy trading of RGS shares after it announced a new credit facility to pay of its debts. 
Via InvestorPlace
Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock
Nvidia stock is up on Tuesday after shares of NVDA got an increased price target from Jefferies analysts alongside praise. 
Via InvestorPlace
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
This is a matchup that the latecomer might not be able to win. 
Via The Motley Fool
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
Novo Nordisk and Eli Lilly dominate the market for GLP-1 drugs, and are racing ahead to produce more of them. 
Via InvestorPlace
Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China
Novo Nordisk's weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.